Expression levels of the cell surface glycoprotein, CD7, and the serine protease, elastase 2 (ELA2), in the leukemic cells of patients with chronic myeloid leukemia (CML) have been associated with clinical outcome. This evidence concerns the gene CD7 and chronic myelogenous leukemia, BCR-ABL1 positive.